Jaffer Ajani, MD, on Metastatic Gastroesophageal Cancers: Expert Perspective
2016 NCCN Annual Conference (1)
Jaffer Ajani, MD, of The University of Texas MD Anderson Cancer Center, discusses the importance of HER2/neu testing and other aspects of treating patients with advanced gastroesophageal adenocarcinoma.
Rogerio Lilenbaum, MD, of Yale Cancer Center/Smilow Cancer Hospital, discusses the importance of tumor profiling for non–small cell lung cancer and strategies for treating EGFR-positive disease in the first-line setting.
Jeffrey Jones, MD, MPH, of the Ohio State University Comprehensive Cancer Center, discusses the use of small molecule inhibitors in developing an individualized treatment plan for patients with CLL.
Joseph V. Simone, MD, of the Simone Consulting Company, gives his expert perspective on the important messages of this year’s meeting.
Douglas E. Wood, MD, of the University of Washington, discusses important new developments in early detection, the need to educate primary care physicians and patients, and the potential to save up to 15,000 lives each year.
Anne Covey, MD, of Memorial Sloan Kettering Cancer Center, discusses the role of ablation and arterial-directed therapy in the treatment of hepatocellular carcinoma.